Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Announces Target Price $19
Integra LifeSciences Is Maintained at Hold by Truist Securities
Integra Lifesciences Analyst Ratings
Argus Upgrades Integra LifeSciences to Buy From Hold, Price Target Is $28
Integra Lifesciences Analyst Ratings
Citizens Capital Markets Reiterates Market Outperform on Integra Lifesciences, Maintains $35 Price Target
Morgan Stanley Maintains Integra Lifesciences(IART.US) With Sell Rating, Maintains Target Price $20
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating
A Quick Look at Today's Ratings for Integra Lifesciences(IART.US), With a Forecast Between $20 to $35
Integra Lifesciences Faces Supply Chain Challenges and Conservative Outlook, Leading to Sell Rating
BTIG Remains a Hold on Integra Lifesciences (IART)
BTIG Maintains Integra Lifesciences(IART.US) With Hold Rating
BTIG Maintains Integra Lifesciences(IART.US) With Hold Rating
Sell Rating Issued for Integra Lifesciences Amidst FDA Warning and Leadership Changes
BofA Securities Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $21
Wells Fargo Maintains Integra Lifesciences(IART.US) With Hold Rating
Wells Fargo Sticks to Its Hold Rating for Integra Lifesciences (IART)
Morgan Stanley Initiates Integra Lifesciences(IART.US) With Sell Rating, Announces Target Price $20
J.P. Morgan Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $24
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Maintains Target Price $26